XToll, a recombinant chaperonin 10 as an anti-inflammatory immunomodulator.
CBio Ltd, under license from the University of Queensland, is developing a recombinant form of chaperonin 10, known as XToll, for the potential anti-inflammatory treatment of rheumatoid arthritis, psoriasis and multiple sclerosis. All three indications have been evaluated in phase IIa clinical trials. By May 2005, a phase IIa trial for Crohn's disease had been terminated due to slow recruitment. The company has not disclosed plans for future development for this indication.
van Eden
Willem
W
University of Utrecht, Institute of Infectious Diseases and Immunology, Yalelaan 1, 3584CL Utrecht, The Netherlands. w.vaneden@uu.nl
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology; D001327:Autoimmune Diseases / Q000188:drug therapy*; D018835:Chaperonin 10 / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology; D011565:Psoriasis / Q000188:drug therapy / Q000276:immunology; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D000893:Anti-Inflammatory Agents; D018835:Chaperonin 10; D007155:Immunologic Factors; D011994:Recombinant Proteins